TORONTO--(Marketwire - January 4, 2011) - Cynapsus Therapeutics Inc. ("Cynapsus") (formerly Cannasat Therapeutics Inc.) (TSX-V: CTH) today announced that on December 31, 2010, it executed a Definitive License Agreement with IntelGenx Corp. ("IntelGenx"), its former development partner, whereby IntelGenx agrees to pay a royalty on future sales of the INT0010 (formerly Relivar), a buccal/sublingual formulation of THC (dronabinol) for the symptomatic management of Multiple Sclerosis induced neuropathic pain and other conditions. MORE>>
